1. Scrip
  2. >>Therapy Areas

Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting

$3bn More In Sales Projected

 
• By Ayisha Sharma

The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a pivotal breast cancer trial earlier than expected, with success in the intermediate risk group representing a $4bn opportunity untapped by rival Eli Lilly.  

Two teapots, one with pink lid, one with no lid and dark hole, representing breasts and breast cancer
The Risk Of Breast Cancer Returning Peaks Three Years After Diagnosis • Source: Shutterstock

Novartis AG’s CDK4/6 inhibitor Kisqali has reduced risk of disease recurrence in the pivotal NATALEE trial in early breast cancer (EBC) patients, with positive data in the intermediate-risk population differentiating it from rival Eli Lilly and Company’s Verzenio.

NATALEE enrolled 5,100 people with HR+/HER2- EBC including those with stage IIA, IIB and III tumors regardless of nodal involvement....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.